Biotrial Rejects French Phase I Inquiry Findings, Says Action Plan Already In Place
Executive Summary
The French health ministry has given Biotrial, the CRO that ran the disastrous Phase I FAAH inhibitor study in Rennes, one month in which to draw up an action plan to ensure that the "major failings" seen in the trial "cannot happen again." If it fails to do so it may lose its authorization to conduct clinical trials.